Clinical trials: Anti-Retroviral Agents
HIV Infections, Sleep Disorder
Assessment of Sleep Disordersin People Living With HIV in the Era of New Antiretroviral Therapies in North of France
People living with HIV (PLHIV) appear to present with sleep-related complaints more frequently than the general population, with a prevalence of 50-70%. The latest French multi-center epidemiological data are dated.
- Trial name
- SANDMAN (NCT06441383)
- Testing
- Pittsburgh Sleep Quality Index
- Where
- France
- Volunteers
- 1,100 people, healthy volunteers welcome
- Sponsor
- Tourcoing Hospital
HIV Infections
A Study of CI-1012 in HIV-Infected Patients
The purpose of this study is to see if it is safe and effective to give CI-1012 to HIV-infected patients who do not have any symptoms of the disease. This study also examines how the body handles CI-1012.
- Trial name
- NCT00002196
- Testing
- CI-1012
- Where
- 4 sites in United States
- Volunteers
- 32 people
- Sponsor
- Parke-Davis
HIV Infections, HIV Seronegativity
The Effect of Efavirenz and Nelfinavir on the Blood Levels of Certain Lipid-Lowering Drugs
The purpose of this study is to find out whether certain anti-HIV drugs (efavirenz [EFV] and nelfinavir [NFV]) affect the amount of certain fat-lowering drugs (atorvastatin, pravastatin, and simvastatin) in the blood.
- Conditions
- HIV Infections, HIV Seronegativity, Lipodystrophy
- Trial name
- NCT00017758
- Testing
- Pravastatin sodium, Simvastatin, Atorvastatin calcium
- Where
- 10 sites in United States
- Volunteers
- 56 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV Infections
The Maraviroc Central Nervous System (CNS) Study
The purpose of this study is to describe the Central Nervous System exposure of maraviroc in HIV-1 infected subjects receiving a stable antiretroviral regimen, including maraviroc, at steady state.
- Trial name
- NCT00982878
- Testing
- Maraviroc
- Where
- United Kingdom
- Volunteers
- 13 people
- Sponsor
- Imperial College London
HIV Infections
Ritonavir and Agenerase Treatment for Patients Who Have Failed Previous Anti-HIV Treatment
The purpose of this study is to determine if treatment with an anti-HIV drug containing ritonavir and Agenerase is safe and can lower the level of HIV in the blood in patients who have failed an anti-HIV drug treatment containing…
- Trial name
- NCT00006591
- Testing
- Ritonavir, Amprenavir
- Where
- United States
- Sponsor
- Gathe, Joseph, M.D.
HIV-1
The TMC125-C214 Study Provides Early Access to TMC125 for HIV-1 Infected Patients Who Have Failed Multiple Antiretroviral Regimens and Will Also Gather Information on the Long-term Safety and Tolerability of TMC125 Combined With Other Antiretroviral Drugs
The purpose of this study is to provide early access of TMC125 to HIV-1 infected patients who have failed multiple antiretroviral (ARV) regimens.
- Trial name
- NCT00354627
- Testing
- TMC125
- Where
- 304 sites in United States, Belgium and 14 more
- Sponsor
- Tibotec Pharmaceuticals, Ireland
HIV
A Study of the Safety, Tolerability, and Pharmacokinetics of Dolutegravir in Neonates Exposed to HIV-1
The purpose of this study was to evaluate the safety, tolerability, and pharmacokinetics (PK) of dolutegravir (DTG) in infants born to mothers living with HIV-1.
- Trial name
- NCT05406583
- Testing
- Dolutegravir 0.5 mg/kg liquid suspension (starts at 0-5 days of life), Dolutegravir 5 mg Dispersible Tablets (single doses), Dolutegravir 5 mg Dispersible Tablets (chronic dose)
- Where
- 15 sites in United States, South Africa and 1 more
- Volunteers
- 96 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV Infections
The Safety and Effectiveness of Indinavir Plus Ritonavir Plus Two NRTIs in HIV-Infected Patients Who Need Early Intervention Treatment
The purpose of this study is to see if it is safe and effective to give indinavir plus ritonavir plus 2 NRTIs to HIV-infected patients who need early intervention treatment.
- Trial name
- NCT00005118
- Testing
- Indinavir sulfate, Ritonavir
- Where
- 40 sites in United States
- Volunteers
- 100 people
- Sponsor
- Merck Sharp & Dohme LLC
Hiv Infection With Antiretroviral Therapy Indication, CD4 Below 350/µL or Below 15%
Zidovudine / Lamivudine + Nevirapine Twice Daily, Versus Tenofovir + Lamivudine + Nevirapine Once Daily in ARV-Naive Patients
The study will compare the immuno-virological efficacy, and safety, of a once daily antiretroviral combination (tenofovir + lamivudine + nevirapine) versus a twice daily association (fixed dose combination of…
- Trial name
- NCT00199979
- Testing
- Nevirapine
- Where
- France
- Volunteers
- 250 people
- Sponsor
- MEDEX
Hepatitis B Virus, HIV
Antiretroviral Treatment Outcomes in HIV-HBV Co-infected Patients in Southern Africa
This is a prospective HIV cohort that aims to establish causes of liver disease among HIV-infected individuals in Zambia, including viral hepatitis and alcohol.
- Conditions
- Hepatitis B Virus, HIV, Antiretroviral Therapy, Africa
- Trial name
- NCT02060162
- Testing
- Standard of care
- Where
- Zambia
- Volunteers
- 897 people
- Sponsor
- University of Alabama at Birmingham
HIV
Imaging and Biopsy of People With HIV-1 Undergoing Analytic Treatment Interruption
Background: Human immunodeficiency virus (HIV) infects CD4 T cells. There is no cure for HIV. People with HIV need to take daily medications called antiretroviral therapy (ART) to control their infection.
- Trial name
- NCT05419024
- Testing
- Acute Treatment Interruption
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- National Cancer Institute (NCI)
HIV Infections
Treatment With Interleukin-2 (IL-2) Plus Combination Anti-HIV-Drug Therapy (HAART) for Patients Formerly in ACTG 328
This study examines the long-term effects of interleukin-2 (IL-2) in combination with anti-HIV drugs, or highly active antiretroviral therapy (HAART).
- Trial name
- NCT00000923
- Testing
- Indinavir sulfate, Lamivudine, Stavudine
- Where
- 12 sites in United States
- Volunteers
- 110 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Human Immuno-deficiency Virus (HIV) Disease
A Study to Assess Change in Disease Activity, Adverse Events, and How the Drug Moves Through the Body in Adult Participants Living With Human Immunodeficiency Virus (HIV) Receiving Intravenous (IV) Infusion or Subcutaneous (SC) Injection of Budigalimab and/or ABBV-382
Human immuno-deficiency virus (HIV) is the virus that causes Acquired Immuno-Deficiency Syndrome (AIDS). HIV disease is considered to be a chronic disease requiring lifelong therapy.
- Trial name
- NCT06032546
- Testing
- Budigalimab, ABBV-382
- Where
- 80 sites in United States, Belgium and 11 more
- Volunteers
- 163 people
- Sponsor
- AbbVie
HIV-1
A Study to Evaluate the Efficacy and Safety of (D/C/F/TAF) Once Daily Fixed Dose Combination (FDC) Regimen in Newly Diagnosed, Antiretroviral Treatment-naive Human Immunodeficiency Virus Type 1 (HIV-1) Infected Participants Receiving Care in a Test and Treat Model of Care
The purpose of this study is to assess the efficacy of Darunavir/ Cobicistat/ Emtricitabine/ Tenofovir Alafenamide (D/C/F/TAF) fixed-dose combination (FDC) in a Test and Treat model of care in newly diagnosed human…
- Trial name
- NCT03227861
- Testing
- DRV 800 mg + COBI 150 mg + FTC 200 mg + TAF 10 mg FDC
- Where
- 16 sites in United States
- Volunteers
- 109 people
- Sponsor
- Janssen Scientific Affairs, LLC
Streptococcal Pneumonia, HIV/AIDS
Immunogenicity and Safety of 13-valent Pneumococcal Conjugate Vaccine Among HIV-infected Adults
HIV-infected patients are 30- to 100-fold more susceptible to invasive pneumococcal diseases. Pneumococcal vaccination is the best way to decrease the large pneumococcal disease burden, but the optimal timing of vaccination is…
- Trial name
- NCT03838497
- Testing
- Prevenar13
- Volunteers
- 70 people
- Sponsor
- Korea University Guro Hospital
HIV (Human Immunodeficiency Virus), AIDS (Acquired Immune Deficiency Syndrome)
Antiretroviral Therapy and Inflammatory and Coagulation Biomarkers: iMACS Study
The aim of this study is to develop and follow a cohort of human immunodeficiency virus (HIV)-infected adults who are starting HIV drugs at health facilities in Kenya.
- Conditions
- HIV (Human Immunodeficiency Virus), AIDS (Acquired Immune Deficiency Syndrome), Tuberculosis, Non-communicable Diseases (NCD)
- Trial name
- iMACS (NCT02027480)
- Where
- 9 sites in Kenya
- Volunteers
- 685 people
- Sponsor
- Columbia University
HIV-1-infection
Safety and Efficacy of Neutralizing Antibodies and Vaccination for Induction of HIV Remission
This is a phase I, randomized, open-label trial to investigate the safety of VRC07-523LS, PGDM1400LS and N-803 in combination with Ad26.Mos4.HIV, MVA-Bavarian Nordic (BN)-HIV and A244d11gp120/ALFQ vaccination, and the impact on…
- Trial name
- RV582 (NCT05769569)
- Testing
- VRC07-523LS, PGDM1400LS, N-803
- Where
- 2 sites in Thailand
- Volunteers
- healthy volunteers welcome
- Sponsor
- Henry M. Jackson Foundation for the Advancement of Military Medicine
HIV Infection Primary
Safety and Impact of Dasatinib on Viral Persistence and Inflammation in People With HIV Under Antiretroviral Treatment
The goal of this clinical trial is to evaluate the safety, tolerability and Impact of low dose Dasatinib in People with Human Immunodeficiency Virus (PWH) on suppressive Combined Antiretroviral Therapy (cART),.
- Trial name
- NCT05780073
- Testing
- Dasatinib 70 mg
- Where
- Spain
- Volunteers
- 60 people
- Sponsor
- Fundació Institut Germans Trias i Pujol
Healthy, HIV Infections
Influence of the MDR1 Genotype on Blood Levels of Indinavir and Saquinavir in Healthy Volunteers
This study will examine whether a particular type of gene (MDR1) in the body can affect blood levels of two protease inhibitors, indinavir and saquinavir, which are used to treat people with HIV.
- Trial name
- NCT00050180
- Testing
- Midazolam, Indinavir, Saquinavir
- Where
- United States
- Volunteers
- 81 people
- Sponsor
- National Institutes of Health Clinical Center (CC)
Infection, Human Immunodeficiency Virus
A Pilot Study Assessing the Integrase Inhibitor GSK1349572 in HIV-infected Persons With Virus Resistant to Raltegravir
Integrase is an enzyme produced by HIV so that the virus can multiply in the human body. GSK1349572 is a new drug in the integrase inhibitor class that prevents the enzyme from working properly and therefore prevents the virus…
- Trial name
- NCT00950859
- Testing
- GSK1349572 (Cohort I), GSK1349572 (Cohort II)
- Where
- 26 sites in United States, Canada and 3 more
- Volunteers
- 51 people
- Sponsor
- ViiV Healthcare
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.